Telix Pharmaceuticals Ltd — Capital/Financing Update 2022

Jan 19, 2022

Market Announcement

==> picture [33 x 50] intentionally omitted <==

20 January 2022

==> picture [451 x 5] intentionally omitted <==

Telix Pharmaceuticals Limited (ASX: TLX) – Trading Halt

Description

The securities of Telix Pharmaceuticals Limited (‘TLX’) will be placed in trading halt at the request of TLX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 24 January 2022 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)

Market Announcement 1/1 ASX Customer Service Centre 131 279 | asx.com.au

20 January 2022 ASX Limited

Telix Pharmaceuticals Limited ACN 616 620 369 Suite 401, 55 Flemington Road North Melbourne, Victoria, 3051 Australia www.telixpharma.com

==> picture [106 x 58] intentionally omitted <==

20 January 2022

Melissa Kostopoulos Compliance Adviser, Listings Compliance (Melbourne) Level 4, North Tower Rialto Towers 525 Collins Street Melbourne VIC 3000 By email: tradinghaltsmelbourne@asx.com.au

Dear Melissa

REQUEST FOR TRADING HALT

Telix Pharmaceuticals Limited (ASX: TLX) (Company) requests an immediate trading halt be granted for all of its securities.

In accordance with Listing Rule 17.1, the Company advises:

• the trading halt is requested pending an announcement regarding a material capital raise;

• the trading halt is requested to apply until the earlier of an announcement by the Company on the completion of the capital raise, or the commencement of normal trading on Monday, 24 January 2022; and

• the Company is not aware of any reason why a trading halt should not be granted.

Authorised for release by the Board of Telix Pharmaceuticals Limited.

==> picture [129 x 43] intentionally omitted <==

Melanie Farris Group Company Secretary